Polarean Imaging PLC
LSE:POLX
Polarean Imaging PLC
Polarean Imaging Plc.operates as a medical drug-device combination company serving the medical imaging market in the United States and internationally. The company is headquartered in Durham, North Carolina and currently employs 21 full-time employees. The company went IPO on 2018-03-29. The firm with its subsidiaries operates in the medical imaging market and develops equipment to enable existing magnetic resonance imaging (MRI) systems. The firm develops equipment that enables existing MRI systems to attain an improved level of pulmonary function imaging and specializes in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualize ventilation. 129Xe gas is being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream. 129Xe used to evaluate pulmonary function and to visualize the lung using MRI. The firm operates in an area of unmet medical need and its technology provides an investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform.
Polarean Imaging Plc.operates as a medical drug-device combination company serving the medical imaging market in the United States and internationally. The company is headquartered in Durham, North Carolina and currently employs 21 full-time employees. The company went IPO on 2018-03-29. The firm with its subsidiaries operates in the medical imaging market and develops equipment to enable existing magnetic resonance imaging (MRI) systems. The firm develops equipment that enables existing MRI systems to attain an improved level of pulmonary function imaging and specializes in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualize ventilation. 129Xe gas is being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream. 129Xe used to evaluate pulmonary function and to visualize the lung using MRI. The firm operates in an area of unmet medical need and its technology provides an investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
